<DOC>
	<DOC>NCT02792686</DOC>
	<brief_summary>This study is an open label, parallel group, single ascending dose, exploratory study performed in a single site (Centre Cap, Montpellier, France).</brief_summary>
	<brief_title>ABX464 First in Man Study</brief_title>
	<detailed_description>This study is an open label, parallel group, single ascending dose, exploratory study performed in a single site (Centre Cap, Montpellier, France). Six subjects per dose group were enrolled into 1 of 4 groups with escalating doses of ABX464 (50, 100, 150 and 200 mg). For each dose group, a first subject was treated, if no adverse event (AE) occurred, a second subject was dosed one hour later. The four last subjects were dosed the day after if no clinically significant AE occurred. Escalation to the following dose level was decided after review of PK and safety data (laboratory results, ECG, vital signs and AEs)</detailed_description>
	<criteria>Healthy volunteers Subject in good health on the basis of medical history, physical examination, vital signs, electrocardiogram (ECG) and routine laboratory safety tests Subject with a BMI of 18 27kg/mÂ² Non smokers or light smokers of less than 10 cigarettes per day Having given their written informed consent Subject with any ongoing infection or disease</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Healthy Volunteers</keyword>
</DOC>